{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T17:40:53Z","timestamp":1773510053409,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.ygyno.2019.12.010","type":"journal-article","created":{"date-parts":[[2019,12,27]],"date-time":"2019-12-27T00:36:48Z","timestamp":1577407008000},"page":"517-522","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making"],"prefix":"10.1016","volume":"156","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1928-9302","authenticated-orcid":false,"given":"Soledad","family":"Jorge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew S.","family":"McFaddin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kemi M.","family":"Doll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn P.","family":"Pennington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara M.","family":"Norquist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin L.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin C.","family":"Pritchard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth M.","family":"Swisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2019.12.010_bb0005","series-title":"Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer (Version 1.2019) [Internet]","author":"National Comprehensive Cancer Network","year":"2019"},{"issue":"4","key":"10.1016\/j.ygyno.2019.12.010_bb0010","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","article-title":"Inherited mutations in women with ovarian carcinoma","volume":"2","author":"Norquist","year":"2016","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.ygyno.2019.12.010_bb0015","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ygyno.2011.01.020","article-title":"Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer","volume":"121","author":"Zhang","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2019.12.010_bb0020","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"44","key":"10.1016\/j.ygyno.2019.12.010_bb0025","doi-asserted-by":"crossref","first-page":"18032","DOI":"10.1073\/pnas.1115052108","article-title":"Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing","volume":"108","author":"Walsh","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.ygyno.2019.12.010_bb0030","doi-asserted-by":"crossref","first-page":"236","DOI":"10.20892\/j.issn.2095-3941.2016.0024","article-title":"Genetic and molecular changes in ovarian cancer","volume":"13","author":"Hollis","year":"2016","journal-title":"Cancer Biol Med"},{"issue":"15_suppl","key":"10.1016\/j.ygyno.2019.12.010_bb0035","doi-asserted-by":"crossref","first-page":"5544","DOI":"10.1200\/JCO.2016.34.15_suppl.5544","article-title":"Prevalence of somatic mutations in risk genes including BRCA1\/2 in consecutive ovarian cancer patients (AGO-TR-1 study)","volume":"34","author":"Hahnen","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"34","key":"10.1016\/j.ygyno.2019.12.010_bb0040","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1200\/JCO.2008.16.1703","article-title":"\u201cBRCAness\u201d syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations","volume":"26","author":"Tan","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.ygyno.2019.12.010_bb0045","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jama.2011.1456","article-title":"Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer","volume":"306","author":"Yang","year":"2011","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.ygyno.2019.12.010_bb0050","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","article-title":"Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer","volume":"5","author":"Konstantinopoulos","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ygyno.2019.12.010_bb0055","series-title":"Genetic\/Familial High-Risk Assessment: Breast and Ovarian (Version 3.2019) [Internet]","author":"National Comprehensive Cancer Network","year":"2019"},{"issue":"4","key":"10.1016\/j.ygyno.2019.12.010_bb0060","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-17-1327","article-title":"Mutations in homologous recombination genes and outcomes in ovarian carcinoma patients in GOG 218: an NRG oncology\/gynecologic oncology group study","volume":"24","author":"Norquist","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"22","key":"10.1016\/j.ygyno.2019.12.010_bb0065","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1200\/JCO.2009.27.2997","article-title":"Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer","volume":"28","author":"Hennessy","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.12.010_bb0070","unstructured":"Moore K, Colombo N, Scambia G, Kim B-G, Oaknin A, Friedlander M, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med.. 2018 Oct 21;NEJMoa1810858."},{"issue":"1","key":"10.1016\/j.ygyno.2019.12.010_bb0080","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10106","key":"10.1016\/j.ygyno.2019.12.010_bb0085","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet (London, England)"},{"issue":"22","key":"10.1016\/j.ygyno.2019.12.010_bb0090","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.ygyno.2019.12.010_bb0095","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.ygyno.2019.12.010_bb0100","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"issue":"28","key":"10.1016\/j.ygyno.2019.12.010_bb0105","doi-asserted-by":"crossref","first-page":"12629","DOI":"10.1073\/pnas.1007983107","article-title":"Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing","volume":"107","author":"Walsh","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.ygyno.2019.12.010_bb0110","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1214\/ss\/1009213286","article-title":"Interval estimation for a binomial proportion","volume":"16","author":"Brown","year":"2001","journal-title":"Stat. Sci."},{"issue":"6","key":"10.1016\/j.ygyno.2019.12.010_bb0115","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/bjc.2013.70","article-title":"BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a gynecologic oncology group study","volume":"108","author":"Lesnock","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"15_suppl","key":"10.1016\/j.ygyno.2019.12.010_bb0120","doi-asserted-by":"crossref","first-page":"5545","DOI":"10.1200\/JCO.2017.35.15_suppl.5545","article-title":"Somatic mutations in homologous recombination pathway genes in ovarian cancer","volume":"35","author":"Aghajanian","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.12.010_bb0125","series-title":"Society of Gynecologic Oncology 50th Annual Meeting","article-title":"Costs and benefits of tumor testing for BRCA mutations in high-grade serous ovarian cancer as a triage for confirmatory genetic testing","author":"Kwon","year":"2019"},{"issue":"29","key":"10.1016\/j.ygyno.2019.12.010_bb0130","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1200\/JCO.2018.78.4777","article-title":"Cancer risks for PMS2-associated lynch syndrome","volume":"36","author":"Ten Broeke","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2019.12.010_bb0135","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ygyno.2018.11.017","article-title":"Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: analysis of KEYNOTE-028","volume":"152","author":"Varga","year":"2019","journal-title":"Gynecol Oncol [Internet]"},{"issue":"6349","key":"10.1016\/j.ygyno.2019.12.010_bb0140","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819318025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819318025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:48:15Z","timestamp":1758772095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825819318025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0090825819318025"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.12.010","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}